Sunshine Lake Pharma Co., Ltd. (HKG:6887)
Hong Kong · Delayed Price · Currency is HKD 46.00
-0.42 (-0.90%)
At close: Oct 30, 2025
Sunshine Lake Pharma Company Description
Sunshine Lake Pharma Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical products for the treatment of infectious diseases, chronic diseases, and oncology.
It offers Kewei for the treatment of influenza; Dongweien for the treatment of hepatitis C; and generic drugs for the treatment of infections caused by sensitive bacteria, namely Clarithromycin, Levofloxacin, and Moxifloxacin Hydrochlorid, as well as active pharmaceutical ingredients.
The company also engages in the wholesale, retail, import, and export of drugs. The company was formerly known as Sunshine Lake Pharma Ltd. The company was incorporated in 2001 and is based in Dongguan, China.
Sunshine Lake Pharma Co., Ltd.
| Country | China |
| Founded | 2001 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 4,861 |
| CEO | Wenjia Li |
Contact Details
Address: HEC Scientific Park Dongguan China | |
| Website | hecpharm.com |
Stock Details
| Ticker Symbol | 6887 |
| Exchange | Hong Kong Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | CNY |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Wenjia Li | Chief Executive Officer |
| Qiang Zhang | Chief Financial Officer |